Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

Market Cap	37.91B +100.3%
Revenue (ttm)	872.53M -12.3%
Net Income	-355.81M
EPS	-0.39
Shares Out	919.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,073,773
Open	40.30
Previous Close	38.96
Day's Range	38.62 - 41.45
52-Week Range	31.40 - 71.71
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About SHE:300255

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology de...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,194
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300255

Financial Performance

In 2025, SHE:300255's revenue was 875.13 million, a decrease of -15.10% compared to the previous year's 1.03 billion. Losses were -357.90 million, 43.5% more than in 2024.